Phagocytic cell NADPH oxidase (NOX) generates reactive oxygen species (ROS) as part of innate immunity. Unfortunately, ischemia can also induce this pathway and inflict damage on native cells. The voltage-gated proton channel Hv1 enables NOX function by compensating cellular loss of electrons with protons. Accordingly, we investigated whether NOX-mediated brain damage in stroke can be inhibited by suppression of Hv1. We found that mouse and human brain microglia, but not neurons or astrocytes, expressed large Hv1-mediated currents. Hv1 was required for NOX-dependent ROS generation in brain microglia in situ and in vivo. Mice lacking Hv1 were protected from NOX-mediated neuronal death and brain damage 24 h after stroke. These results indicate that Hv1-dependent ROS production is responsible for a substantial fraction of brain damage at early time points after ischemic stroke and provide a rationale for Hv1 as a therapeutic target for the treatment of ischemic stroke. 
a r t I C l e S During ischemia, reactive molecules containing oxygen (ROS) are produced that rapidly react with lipids, proteins, cofactors and DNA, which in turn activate apoptotic pathways 1 . The results of recent clinical trials with antioxidants, however, have been disappointing 2 . One of several sources of oxidative stress in the brain is NOX, a membrane-bound enzyme that is abundantly expressed in phagocytic cells, including microglia 3 . NOX-mediated ROS production may have evolved as a defense against invading bacteria, but it nonselectively damages cells such as neurons and glia 4 . NOX and ROS are consistently reported to participate in the pathogenesis of cerebral ischemia injury; NOX2 or NOX4 knockout mice exhibit less brain injury after stroke 5, 6 . Thus, reducing NOX-related oxidative stress could ameliorate neuronal damage in ischemic stroke.
NOX transfers electrons across the plasma membrane, rapidly depolarizing and acidifying these cells. Given that excessive depolarization and intracellular acidification inhibit further expulsion of electrons, a charge-compensating mechanism is needed to maintain NOX activity 7, 8 . By sensing both voltage and pH gradients, the voltagegated proton channel Hv1 is ideally suited to the task of charge compensation for NOX activation 9, 10 . Deletion or inhibition of Hv1 (also known as Hvcn1) greatly reduced NOX-dependent ROS production in leukocytes and bone marrow cells 11, 12 . Thus, Hv1 is a unique target for controlling multiple NOX activities and ROS production.
Hv1 modulates B-cell activation 13 , basophil histamine release 14 , and acid secretion from airway epithelium 15 and human spermatozoa 16 . Whether Hv1 is functionally expressed in mammalian brain neurons and glia is unknown, but the early discovery of proton currents in snail neurons has fostered this perception 17 . The presence of voltage-gated proton current in situ (that is, in the brain) has been debated 18, 19 . Thus, it has not been established whether Hv1 functions in vivo in resident brain cells and, if so, whether Hv1 exerts its function through a common NOX mechanism or whether Hv1 is crucial for oxidative stress-related brain disorders. We sought to characterize Hv1 in native brain cells and investigate its potential role in neuronal damage in ischemic brain injury.
RESULTS

Hv1 mediates the proton currents in brain microglia
We did not detect Hv1 protein in whole brain lysates when compared with an Hv1-rich tissue such as spleen (Fig. 1a) . This raised the question of whether Hv1 is restricted to a particular cell type in the brain. Indeed, we found high levels of Hv1 protein in microglia, the principal resident immune response cells in the brain, but not in neurons (Fig. 1b) . Quantitative real-time PCR (RT-PCR) detected Hv1 mRNA in the brain and in isolated cultured neurons (Supplementary Fig. 1 ). We then examined functional expression of Hv1 in native cells of the brain. Visual identification of microglia was enabled using transgenic mice (Cx3cr1-GFP/+) in which microglia are selectively labeled with GFP (Fig. 1c) . A large voltage-gated, slowly activating outward current was recorded in whole-cell patch-clamp recordings from microglia in mouse hippocampal brain slices (Fig. 1d) . As is characteristic of Hv1, increasing intracellular pH (pH i ) decreased outward current and increased the threshold for current activation (V thr ; Fig. 1d,e) . Tail currents were elicited with different pH gradients to estimate the reversal potential (Fig. 1f) , differing only marginally from values calculated by the Nernst equation (Fig. 1g) as a result of proton depletion 7 . Similar proton currents were observed in cortical microglia. Zn 2+ , the well-established antagonist to Hv1 (refs. 9, 20) , inhibited the proton current in a concentration-dependent manner by shifting V thr to depolarized potentials (Fig. 2a,b) . Finally, the voltagegated proton current was not detected in microglia from Hv1 global knockout (Hv1 −/− ) mice (Fig. 2a,c) . These data indicate that Hv1 is functionally expressed in mouse brain microglia in situ.
Previous work reported that proton currents were absent in rat hippocampal microglia 18 . We performed whole-cell recording in hippocampal microglia from rats and mice and found that voltagegated proton currents were much larger in mice; rat proton current was only 8% of that in mice under our conditions (glutamate receptor antagonists were not used during preparation of brain slices; Supplementary Fig. 2) . A previous report found that Hv1 was expressed in mature, but not neonatal, mouse brain 11 . However, we found that proton currents were consistently present after birth and exhibited similar current amplitudes in hippocampal microglia from postnatal day 0-2 (P0-2), P7-9 and P21-23 mice ( Supplementary  Fig. 3 ). Appreciable Hv1 protein and proton-selective currents inhibited by Zn 2+ were also recorded from cultured human microglia (Fig. 2d-g and Supplementary Fig. 4 ) and mRNA was detected in microarrays of human brain (http://www.alleninstitute.org/). However, it is important to point out the marked differences in amplitude between proton current expressed in situ (rat microglia in brain slices) and in cultured rat microglia 18, 21 . Thus, it is not known whether human microglia in situ have large Hv1 currents.
Next, we determined whether Hv1 current is present in hippocampal neurons. No measureable voltage-gated proton current was detected, although we recorded a current that may have been previously misidentified as a proton current 22 . This nonselective (E rev = 0) outward current was present in Hv1 −/− mice (Fig. 2h) , was not inhibited by Zn 2+ and persisted after increasing pH i from pH i 5.5 to pH i 7.2 ( Fig. 2h,i) . Similarly, we did not observe Hv1 current in cortical neurons from wild-type mice. In addition, no proton currents were detected in astrocytes from young (Fig. 2j) or adult mice (Supplementary Fig. 5 ). Field recordings performed in the CA1 region of wild-type and Hv1 −/− hippocampal slices revealed no difference in the input-output relation of field-stimulated excitatory postsynaptic potentials, paired-pulse facilitation or high-frequency stimulation-induced long-term potentiation (LTP) between wild-type and Hv1 −/− mice (Supplementary Fig. 6 ). Finally, in two learning and memory assays (Y maze spontaneous alternation and visual discrimination tests), no difference was found between wild-type and Hv1 −/− mice (Supplementary Fig. 7 ). We therefore conclude that Hv1 is either not present or is not functionally relevant in the neurons or astrocytes that we tested under normal conditions. Hv1 in acid extrusion and NOX-dependent ROS production Hv1 mediates outward proton current that scales with depolarization and the pH gradient. Thus, the Hv1 current is largest when cells are acidified and depolarized. But does Hv1 regulate H + homeostasis under normal conditions? Cultured microglia were acid loaded using the rebound acidification technique 23 by perfusing cells with a 20 mM NH 4 Cl pulse. The recovery rate of pH i was then calculated. The resting pH i of microglia was similar in wild-type (7.10 ± 0.05, n = 32) and Hv1 −/− microglia (7.19 ± 0.03, n = 38). After intracellular acidification by NH 4 Cl washout, pH i recovery rates were similar in wild-type and Hv1 −/− microglia in the presence of high Na + . In contrast, pH i recovery was abolished in the absence of Na + (NMDG replacement) in both wild-type and Hv1 −/− microglia (Fig. 3a,b) . These results suggest that a Na + -dependent mechanism (such as the Na/H exchanger), but not Hv1, mediates acid extrusion during intracellular acidification (a) Hv1 protein was detected by western blot (using antibody α1-Hv1) in the spleen, but not in whole brain lysates (also see Supplementary Fig. 14a ).
WT, wild type. (b) Hv1 protein was detected by western blot (α1-Hv1) in cultured microglia, but not in cultured neurons (also see Supplementary  Fig. 14b ). npg a r t I C l e S as low as pH 6.0. However, pH i rapidly recovered when cells were depolarized with a high K + solution. The recovery of pH i was largely reduced in the presence of Zn 2+ (100 µM) and was completely abolished in Hv1 −/− microglia (Fig. 3a,b) . Thus, Hv1 is not critical for H + homeostasis under resting conditions, but is engaged in microglial acid extrusion following depolarization.
A well-documented function of Hv1 is the transfer of positive charge out of the cytoplasm in compensation for NOX-mediated electron extrusion 7 . Time-lapse confocal imaging was used to measure ROS generation from microglia in the stratum radiatum of the hippocampal CA1 region. Dihydroethidium (DHE) was perfused into hippocampal slices from Cx3cr1-GFP/+ mice and ROS production was measured as the oxidation of DHE to ethidium (Fig. 3c) . Phorbol ester (PMA) induced the oxidative burst in wild-type brain slice microglia, measured as a slow increase in ethidium fluorescence ( Fig. 3c and Supplementary Movie 1). After 20 min of PMA exposure, fluorescence increased approximately eightfold more than that measured from microglia that were not exposed to PMA (Fig. 3d,e) . The increase was abolished by the NOX inhibitors diphenyleneiodonium (DPI, 30 µM) and apocynin (300 µM) and by the Hv1 inhibitor Zn 2+ (100 µM). Moreover, no significant increase in ethidium fluorescence was found in Hv1 −/− microglia after PMA treatment (P = 0.337; Fig. 3c-e) . PMA did not markedly lower pH i in wild-type microglia, but did induce substantial intracellular acidification in Hv1 −/− microglia under Na + -free conditions (Fig. 3f) . The PMA-induced intracellular acidification was dependent on NOX activation, as it was inhibited in the presence of DPI (10 µM) (Fig. 3f) . These results indicate that Hv1 is required for NOX-dependent ROS production and alleviation of NOX-dependent acidification in brain microglia, as has been shown extensively in phagocytic blood cells 13 .
Brain microglia extend processes to damaged cells in response to injury signals, such as ATP 24, 25 . To determine whether removal of Hv1 affects this microglial response, we used time-lapse confocal imaging to monitor ATP-induced microglial terminal chemotaxis in acute brain slices from wild-type and Hv1 −/− mice. The number and speed of hippocampal microglial terminal extensions toward an ATP-containing pipette were indistinguishable between wild-type and Hv1 −/− mice ( Fig. 3g and Supplementary Movie 2) . In addition, no difference was found in microglial migration toward TNF-α and MCP-1 in wild-type and Hv1 −/− cultured microglia (Fig. 3h) . We conclude that Hv1 is important for microglial ROS production, but is not required for chemotaxis or migration.
Hv1 is critical for brain damage in mouse ischemic stroke NOX is a common mediator of microglia-mediated neuronal damage in stroke 4, 26 . To determine whether indirect inhibition of NOX activity by deletion of Hv1 ameliorates ischemic stroke damage, we employed the mouse middle cerebral artery occlusion (MCAO) model. Wild-type and Hv1 −/− mice were subjected to right-sided permanent ligature MCAO (pMCAO) for 24 h under isoflurane anesthesia. The resulting brain injury was estimated by standard 2,3,5-triphenyltetrazolium chloride (TTC) staining, a colorimetric redox npg a r t I C l e S indicator that distinguishes metabolically active from inactive tissue (Fig. 4a) . The infarct volume in Hv1 −/− mice was significantly smaller than that in wild-type mice after pMCAO (P = 0.004; Fig. 4b ). We also found similar reduction of infarct volume in Hv1 −/− mice compared with that in wild-type mice in initial experiments using ketamine/xylazine as anesthetics (Fig. 4b) . The difference in brain damage was functionally relevant, as Hv1 −/− mice had substantially better neurological scores than wild-type mice (Fig. 4c) . Additional assays for ischemia-induced brain damage were used to further characterize the effect of Hv1 deficiency on the response to pMCAO under ketamine and xylazine anesthesia. First, T2-weighted magnetic resonance imaging (MRI) was used to examine brain injury 24 h after pMCAO in wild-type and Hv1 −/− mice (Fig. 4d) . We found that the injury volume in Hv1 −/− mice was significantly smaller than that in wild-type mice after pMCAO (P = 0.024; Fig. 4e and Supplementary Movie 3). We then examined positron emission tomography (PET) imaging of 18F-labeled 2-fluoro-2-deoxy-dglucose ( 18 F-FDG) uptake, which reflects brain glucose metabolism 27 , in wild-type and Hv1 −/− mice before and 24 h after pMCAO. Although there was no difference in 18 F-FDG uptake between wild-type and Hv1 −/− mice before pMCAO, right hemispheric 'cold spots' were significantly smaller in Hv1 −/− mice 24 h after pMCAO (P = 0.013; Supplementary Fig. 8a,b) . Blood pressure before and at various time points after pMCAO did not differ between wild-type and Hv1 −/− mice (Supplementary Fig. 8c ). Brains of wild-type and Hv1 −/− mice compared 72 h after pMCAO revealed a similar degree of protection ( Supplementary Fig. 8d,e) . Finally, a transient MCAO (tMCAO) stroke model, in which mice were subjected to 2 h of occlusion followed by 22 h of reperfusion, revealed significantly smaller infarct volumes and improved neurological function after tMCAO in Hv1 −/− mice when compared with wild-type mice (P = 0.018; Supplementary  Fig. 9a-c) . Taken together, these results indicate that Hv1 supports NOX activity and NOX-induced brain damage, and suggest that inhibition or block of Hv1 will lessen brain damage after stroke. Given that we observed similar phenotypes after using either isoflurane or ketamine and xylazine as anesthetics in MCAO surgeries, the primary observed effect of Hv1 on brain injury likely occurs via NMDA receptor-independent mechanisms. 
a r t I C l e S
Significantly larger proton currents and lower activation thresholds were recorded from microglia in the ischemic penumbra 24 h after pMCAO (P = 0.023; Fig. 4f,g ). Neither an increase in outward K + currents 28 (eliminated by tetramethylammonium (TMA) replacement) nor a change in cell membrane area (measured by membrane capacitance) accounted for the increase in outward current (Fig. 4g) . We also observed an increase in Hv1 protein in whole brain lysates after stroke (Fig. 4h) . Fig. 14d ). Spleen was used as a control (n = 3). Data are mean ± s.e.m. npg a r t I C l e S recording via the perforated-patch method (to preserve physiological intracellular conditions) rapidly enhanced proton currents that were inhibited by ZnCl 2 (Supplementary Fig. 10b,c) . TRPM2 channels were present in microglia, as revealed by intracellular perfusion of ADP ribose 29 , but this current was not measurably activated by H 2 O 2 perfusion under our conditions (Supplementary Fig. 10a ).
Microglial Hv1 contributes to neuronal death after ischemia
To directly test whether brain damage was reduced by suppression of Hv1 function, we immunostained the peri-infarct area in wild-type and Hv1 −/− mice 24 h after pMCAO. Significantly larger increases in caspase-3-and TUNEL-positive neurons (NeuN + ) were found after stroke in wild-type than in Hv1 −/− mice (P = 0.029; Fig. 5a,b) . Similarly, 30 min of oxygen glucose deprivation (OGD) 30 induced significantly more neuronal death in wild-type microglia and neuronal co-cultures compared with Hv1 −/− co-cultures (P = 0.001; Fig. 5c-e) . Cellular necrosis, as indicated by lactate dehydrogenase (LDH) release, was significantly higher in wild-type than in Hv1 −/− microglia-neuron co-cultures after OGD (P = 0.035; Fig. 5e ). The microglial Hv1-dependent neuronal death is likely a result of the NOX activation, as pretreatment of the NOX inhibitors DPI (10 µM) and apocynin (100 µM) significantly reduced microglia-induced neuronal death (P = 0.002; Fig. 5f ). However, when DPI and apocynin treatments were used after OGD insult, neuronal protection did not reach significance (DPI, mortality from 38.7 ± 3.7% to 31.6 ± 3.6%, P = 0.30; apocynin, from 39.6 ± 4.5% to 35.1 ± 3.4%, P = 0.51). In addition, microglial Hv1 knockdown by small hairpin RNA (shRNA) reduced microglialdependent neuronal death (Fig. 5f) , suggesting that reduced neuronal death after addition of Hv1 −/− microglia is not a result of compensatory effects. Together, these findings indicate that Hv1 supports NOX activation in the induction of neuronal death after OGD. NMDA receptor activation enhances neuronal NOX activation and ischemia-induced neurotoxicity 31 . As expected, the NMDA receptor blocker MK801 (10 µM) protected neurons in both wild-type and Hv1 −/− neurons (Fig. 5f) . NMDA (10 µM, 12 h) induced a similar degree of nitric oxide (NO) release and cell death in wild-type and Hv1 −/− neurons (Fig. 5g) . NMDA receptor-mediated excitatory postsynaptic currents were not altered in Hv1 −/− mice compared with wild-type mice (Supplementary Fig. 11) . Thus, the reduction of neuronal death in Hv1 −/− mice was not a result of decreased NMDA receptor-mediated excitotoxicity or of effectors of the NMDA receptor, such as NO release.
Microglia Hv1 mediates ROS production after ischemia During ischemic stroke, microglia release ROS, cytokines, glutamate and NO, which increase cell death 32, 33 . Of TNF-α, IL-1β, IL6, npg a r t I C l e S IFN-γ, VEGF, glutamate, NO and ROS, we found that only ROS production was reduced in Hv1 −/− compared with wild-type cultured microglia after OGD (Fig. 6a) . ROS production in microglia was also decreased in brain slices after OGD (OGD was effective, as fieldstimulated excitatory postsynaptic potentials were largely inhibited in field recordings of hippocampal neurons; Fig. 6b ). In the tMCAO model, both neurons and microglia ipsilateral to the MCAO region exhibited substantial increases in ROS production compared with those in the contralateral hemisphere after intraperitoneal injection of DHE in Cx3cr1-GFP/+ mice (Fig. 6c,d ). In the cortex and striatum, microglial ROS production was also much smaller in Hv1 −/− mice than in wild-type mice (Fig. 6c,d ). In addition, ipsilateral microglia were more active in wild-type mice, as assayed by an increase in cell body area, compared with those on the contralateral side (Fig. 6c,e) . Finally, phosphorylation of the NF-κB subunit p65, a critical proinflammatory transcription factor that is affected by ROS signaling in stroke 34 , increased substantially in wild-type mice, but not in Hv1 −/− mice (Fig. 6f) . Together, these results indicate that Hv1 contributes to microglial activation, ROS production and NF-κB phosphorylation in vivo after stroke. If Hv1 protects brain tissue by reducing NOX-driven ROS during ischemia, ROS scavengers should reduce its effects. EUK-207, a mimetic of superoxide dismutase and catalase, is a powerful scavenger in oxidative stress in vivo and is effective in alleviating age-related learning deficits 35 . EUK-207 (20 mg per kg of body weight), injected at 2 and 24 h after pMCAO under ketamine and xylazine anesthesia, reduced the infarction area measured at 72 h in both wild-type and Hv1 −/− mice (Fig. 6g) . Consistent with expectations, the rescue of brain injury by EUK-207 was significantly larger in wild-type than that in Hv1 −/− mice (P = 0.029; Fig. 6h) . The lesser protective effect of EUK-207 in Hv1 −/− mice was not a result of smaller initial lesions in these mice, as MK801 (1 mg per kg, injected 3 and 6 h after pMCAO) was similarly protective in wild-type and Hv1 −/− mice 24 h after pMCAO under isoflurane anesthesia (Fig. 6h) .
Microglial Hv1 contributes to brain damage after stroke NOX1-5, DUOX1 and DUOX2 are all members of the NOX family 3 . In cultured microglia, only Nox2 (also known as Cybb) mRNA was present at substantial levels (Fig. 7a) . Western blotting confirmed the expression of NOX2 protein in microglia and brain and similar levels of NOX2 were observed in wild-type and Hv1 −/− microglia (Fig. 7b) . Notably, there was a significant increase in NOX2 expression in the brain after pMCAO and in microglia after OGD (Fig. 7b) . These results suggest that NOX2 is the primary NOX protein coupled to Hv1 during ROS production.
After stroke, the brain is invaded by blood-borne leukocytes expressing high levels of NOX 36 . To test whether peripheral Hv1 also contributes to ischemic injury, we generated four groups of bone marrow chimeric mice (wild type→wild type, wild type→Hv1 −/− , Hv1 −/− →wild type, Hv1 −/− →Hv1 −/− chimeras) and subjected them to pMCAO 16 d after bone marrow transplantation. Chimeras were confirmed by analyzing overall leukocyte engraftment and neutrophil replacement in recipient mice (Supplementary Fig. 12 ). We found that Hv1 −/− →wild-type mice exhibited similar infarct volumes to those of wild-type→wild-type mice 24 h after pMCAO, whereas wild-type→Hv1 −/− mice showed comparable injury to Hv1 −/− → Hv1 −/− mice (Fig. 7c,d) . Moreover, there was significantly more brain damage in Hv1 −/− →wild-type mice than in wild-type→Hv1 −/− mice (P = 0.038; Fig. 7c,d) . These results suggest that Hv1 in resident microglia primarily supports NOX-mediated brain damage during early stages of ischemic stroke.
DISCUSSION
We found that Hv1 is expressed and functions as a voltage-gated, proton-selective current in mouse and cultured human brain microglia. Microglial Hv1 was required for NOX-dependent ROS generation both in vitro and in vivo. Hv1, by rapidly exporting positive charge (H + ), was required for NOX to effectively transport electrons and generate ROS. Experimentally induced ischemia or metabolic challenge elicited ROS production from microglia and other inflammatory cells. ROS are not entirely detrimental, as they are also cerebral vasodilators and mediators of tissue repair and remodeling following ischemic injury 37 . Nevertheless, neuronal lipids, membrane receptors, intracellular kinases and phosphatases, as well as pro-apoptotic transcription factors 1 , are all targets of ROS that damage brain function (Supplementary Fig. 13 ).
Our ROS imaging experiments revealed that mouse microglial Hv1 was activated and, indeed, required for the majority of NOX-dependent ROS production by microglia in situ. The Hv1 channel is ideally suited for this function, as it was activated only after depolarization. The amount of depolarization needed was inversely proportional to the pH gradient. Under most physiologically relevant conditions, this means that, following cell acidification, less depolarization from rest will be required to allow protons to exit the cell, exactly the conditions npg a r t I C l e S under which NOX is active. Without Hv1, NOX activation will cause substantial depolarization and intracellular acidification that will eventually inhibit NOX activation. One of the many changes defining microglia activation in response to ischemia is the translocation of NOX cytosolic subunits to the plasma membrane, where NOX becomes active 32, 34 . We found that microglial Hv1 contributes substantially to NOX ROS production, supporting NOX-mediated neuronal cell death after stroke. First, PMA-or OGD-induced ROS production was substantially reduced in Hv1 −/− microglia compared with wild-type microglia. Second, ROS production in brain microglia in situ after stroke was reduced in Hv1 −/− mice. Third, reduced neuronal death and brain damage was observed in Hv1 −/− mice compared with wild-type mice after stroke. Fourth, OGD-induced neuronal death in microglia (Hv1 −/− )-neuron co-cultures was less than that in wild-type co-cultures. Fifth, rescue by ROS scavengers was less in Hv1 −/− mice than in wild-type mice. Finally, chimeric mice with wild-type microglia and Hv1 −/− circulating blood cells (Hv1 −/− →wild type) showed more brain damage than mice with Hv1 −/− microglia and wild-type blood cells (wild type→ Hv1 −/− ), establishing that resident microglia are responsible for most of the ROS-mediated brain damage at 24 h following stroke.
All cell types in the brain contain NOX proteins and mice deficient for NOX2 or NOX4 have better stoke outcomes 5, 6 . Astrocytes comprise a substantial proportion of cells in the brain and express NOX1-3 (ref. 38 ), but we did not detect Hv1 currents in mouse astrocytes. We assessed brain tissue damage at 1d after MCAO, but large numbers of circulating blood cells enter the brain at later time points after stroke 39, 40 . Thus, we do not exclude the contribution of Hv1 in later stages of stroke. A caveat to the interpretation of bone marrow chimera experiments is the potential complication of irradiation 41 . Nonetheless, it is unlikely that microglia are the only sources of ROSmediated brain damage, as ROS are released from all metabolically stressed mitochondria. Moreover, microglia may exert important protective effects by producing IL-10 and TGF-β, as well as growth factors in the post-ischemic brain 42 . Thus, the dual protective and destructive effects of microglia should be considered when targeting microglia for stroke treatment.
We found no voltage-gated proton currents in hippocampal or cortical neurons in acute brain slices. Moreover, hippocampal basal synaptic transmission, plasticity or NMDA receptor function did not differ between wild-type and Hv1 −/− mice. NMDA induced a similar degree of cell death in wild-type and Hv1 −/− neurons. Thus, glutamate neurotoxicity is unlikely to underlie Hv1's contribution to brain damage. Finally, given that Hv1 function is important for peripheral blood cells 13, 14 , late effects after stroke require future study.
Currently, therapies for ischemic stroke are limited 43 . Recent studies using NOX inhibitors have conflicting results, perhaps because of poor NOX selectivity 43 . We suggest that Hv1 channels may be more tractable targets for prevention of brain injury during ischemia. Notably, as Hv1 is not functionally expressed in neurons, Hv1 inhibitors should not limit neuronal NOX activity. Our results may also be relevant for other ischemic disorders and ROS-related neurodegeneration.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
